New players in the sepsis-protective activated protein C pathway

Area of Science:

• Immunology
• Sepsis Pathophysiology
• Drug Discovery

Background:

• Recombinant activated protein C (aPC) is a known therapy for severe sepsis.
• The exact molecular and cellular mechanisms of aPC's protective effects are not fully understood.
• Identifying these targets is crucial for optimizing sepsis treatment.

Purpose of the Study:

• To investigate the specific cellular targets of aPC in sepsis.
• To elucidate the role of endothelial cell protein C receptor (EPCR) in aPC's protective function.
• To explore the anti-inflammatory pathways modulated by aPC in lethal sepsis.

Main Methods:

• Expression analysis of EPCR on mouse immune cells.
• In vivo studies assessing aPC's efficacy in mouse models of sepsis.
• Investigation of leukocyte integrin CD11b's role in aPC-mediated anti-inflammatory effects.

Main Results:

• EPCR is specifically expressed on mouse CD8+ dendritic cells.
• CD8+ dendritic cells expressing EPCR are essential for aPC's protection against sepsis lethality.
• Leukocyte integrin CD11b is implicated in aPC's anti-inflammatory actions during sepsis.
• These findings suggest a synergistic control of innate immune responses by aPC.

Conclusions:

• Mouse CD8+ dendritic cells expressing EPCR are critical cellular targets for aPC therapy in sepsis.
• aPC utilizes pathways involving EPCR and CD11b to exert protective and anti-inflammatory effects in sepsis.
• This research provides new insights into the mechanisms of aPC action, potentially guiding future therapeutic strategies for severe sepsis.